How biosimilar priced in US market?
Unlike generics, biosimilars are not highly discounted to it’s patented molecule. Biosimilars are in average around 15-20% lesser price tag (considering WAC*)... Read More
EyePoint Pharmaceuticals and Ocumension Therapeutics’s Exclusive License Agreement to Develop and Commercialize DEXYCU
EyePoint Pharmaceuticals Inc., a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics, a fast-growing ophthalmology focused pharmaceutical... Read More
Helsinn out-licenses Akynzeo and Onicit in Russia to Berlin-Chemie
Helsinn out-licenses Akynzeo (netupitant/palonosetron) and Onicit (palonosetron) for Russia and the CIS region to Berlin-Chemie, the German-based affiliate of Italy’s Menarini Group.... Read More
Acquisition in Pharma: Why Astellas to acquire Xyphos Biosciences?
Astellas Pharma Inc. has agreed to acquire Xyphos Biosciences, Inc. Why Astellas acquired Xyphos? With the acquisition Astellas will gain Xyphos’ novel... Read More
Insight on Alteogen’s non-exclusive licensing deal for ALT-B4 to a top 10 global pharma
South Korean company Alteogen Inc. signed a nonexclusive global license agreement with a top 10 global pharmaceutical company for its recombinant human... Read More
Pharma Strategic Deal: Astellas Pharma to acquire Audentes Therapeutics for about $3 billion
Posted on05 Dec 2019
TagsAstellas, Astellas Pharma, biopharma business development, Pharma Business Development, pharma strategic deal
Comments0
Astellas Pharma Inc. anannounced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00... Read More
Pharma Business Development – Competency Test. Check your competency
Pharma Business Development – Competency Test. Check your competency
Case study: Novartis to acquire The Medicines Company for $9.7 billion, get hold of inclisiran, a cholesterol drug
Novartis, a one of the leading global pharmaceutical company, to acquire The Medicines Company for $9.7 billion. Strategic reasoning of the deal:... Read More
Bayer and Dewpoint Therapeutics co-development deal for cardiovascular and gynecological diseases
Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, today announced an option, research and license agreement... Read More
Sandoz to Acquire Japanese Biz of AGI
Posted on17 Nov 2019
Comments0
Sandoz has entered into an agreement to acquire the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen... Read More